Table 2.
Summary of findings outlining absolute risk differences for overall survival by class a.
| Comparators | Triplet therapy | |||
|---|---|---|---|---|
| Synchronous High Volume | Synchronous Low Volume | Metachronous High Volume | Metachronous Low Volume | |
| 101 fewer deaths per 1000 | 18 more deaths per 1000 | 33 fewer deaths per 1000 | 78 more deaths per 1000 | |
| (from 172 fewer to 10 fewer) | (from 83 fewer to 158 more) | (from 222 fewer to 274 more) | (from 93 fewer to 504 more) | |
| HR: 0.71 (0.53–0.97) | HR: 1.08 (0.65–1.79) | HR: 0.89 (0.36–2.22) | HR: 1.56 (0.40–6.25) | |
| 2164 patients (7 RCTs) | 1055 patients (7 RCTs) | 357 patients (4 RCTs) | 236 patients (3 RCTs) | |
| MLV: 209 deaths per 1000 | Rank 3 | Rank 1 | Rank 2 | Rank 1 |
| 97 fewer deaths per 1000 | 61 fewer deaths per 1000 | 30 fewer deaths per 1000 | 54 fewer deaths per 1000 | |
| (from 135 fewer to 57 fewer) | (from 114 fewer to 2 more) | (from 131 fewer to 98 more) | (from 129 fewer to 168 more) | |
| HR: 0.72 (0.62–0.83) | HR: 0.74 (0.53–1.01) | HR: 0.90 (0.60–1.36) | HR: 0.64 (0.18–2.28) | |
| 1817 patients (3 RCTs) | 757 patients (3 RCTs) | 352 patients (2 RCTs) | 111 patients (1 RCTs) | |
| MLV: 279 deaths per 1000 | Rank 2 | Rank 3 | Rank 3 | Rank 4 |
| 206 fewer deaths per 1000 | 73 fewer deaths per 1000 | 113 fewer deaths per 1000 | 48 fewer deaths per 1000 | |
| (from 255 fewer to 139 fewer) | (from 138 fewer to 20 more) | (from 251 fewer to 125 more) | (from 129 fewer to 200 more) | |
| HR: 0.45 (0.34–0.61) | HR: 0.69 (0.44–1.09) | HR: 0.65 (0.29–1.47) | HR: 0.68 (0.18–2.56) | |
| 2404 patients (8 RCTs) | 1139 patients (9 RCTs) | 403 patients (5 RCTs) | 295 patients (3 RCTs) | |
| MLV: 307 deaths per 1000 | Rank 4 | Rank 4 | Rank 4 | Rank 3 |
| Androgen receptor pathway inhibitor doublet | ||||
| 118 more deaths per 1000 | 14 fewer deaths per 1000 | 31 more deaths per 1000 | 70 fewer deaths per 1000 | |
| (from 10 more to 230 more) | (from 92 fewer to 100 more) | (from 159 fewer to 337 more) | (from 172 fewer to 238 more) | |
| HR: 1.40 (1.03–1.90) | HR: 0.93 (0.56–1.54) | HR: 1.12 (0.45–2.78) | HR: 0.64 (0.16–2.53) | |
| 2164 patients (7 RCTs) | 1055 patients (7 RCTs) | 352 patients (4 RCTs) | 236 patients (3 RCTs) | |
| MLV: 160 deaths per 1000 | Rank 1 | Rank 2 | Rank 1 | Rank 2 |
| 3 more deaths per 1000 | 64 fewer deaths per 1000 | 5 more deaths per 1000 | 117 fewer deaths per 1000 | |
| (from 86 fewer to 97 more) | (from 112 fewer to 2 more) | (from 159 fewer to 264 more) | (from 154 fewer to 58 fewer) | |
| HR: 1.01 (0.76–1.32) | HR: 0.69 (0.47–1.01) | HR: 1.02 (0.45–2.28) | HR: 0.41 (0.24–0.70) | |
| 2403 patients (6 RCTs) | 1108 patients (7 RCTs) | 393 patients (4 RCTs) | 297 patients (5 RCTs) | |
| MLV: 279 deaths per 1000 | Rank 2 | Rank 3 | Rank 3 | Rank 4 |
| 139 fewer deaths per 1000 | 72 fewer deaths per 1000 | 74 fewer deaths per 1000 | 113 fewer deaths per 1000 | |
| (from 165 fewer to 110 fewer) | (from 101 fewer to 41 fewer) | (from 147 fewer to 23 more) | (from 143 fewer to 70 fewer) | |
| HR: 0.63 (0.57–0.70) | HR: 0.65 (0.52–0.80) | HR: 0.73 (0.49–1.09) | HR: 0.43 (0.29–0.64) | |
| 2990 patients (5 RCTs) | 1490 patients (5 RCTs) | 444 patients (3 RCTs) | 481 patients (3 RCTs) | |
| Rank 4 | Rank 4 | Rank 4 | Rank 3 | |
Abbreviations: SHV: synchronous high volume; SLV: synchronous low volume; MHV: metachronous high volume; MLV: metachronous low volume; HR: hazard ratio; RCT: randomized controlled trials.
This table outlines relative and absolute risk estimates of death with triplet therapy and androgen receptor pathway inhibitors. The comparison is directed as treatment (in column) versus comparators (in rows). Each sub column represents the subgroup (synchronous high volume; synchronous low volume; metachronous high volume; metachronous low volume). The relative effect estimates along with their 95% confidence intervals are translated into corresponding intervention risk. Assumed baseline risk of death for each comparator by subgroups is computed as mean of risk of death within the study-follow-up period from the included trials. Absolute risk difference is calculated as the absolute risk difference between corresponding intervention risk and assumed comparator risk. Treatment ranks provided in the cells reflect the rankings of each comparator in a given comparison for a given subgroup. For example, in comparison between triplet therapy and androgen receptor pathway inhibitor doublet therapy in synchronous high-volume subgroup, rank 3 indicates the relative treatment ranking for androgen receptor pathway inhibitor doublet. The "ARPI+D+ADT" triplet refers specifically to regimens with concurrent administration of androgen deprivation therapy, androgen receptor pathway inhibitor, and docetaxel. At this time, apalutamide is not included in this category due to the lack of published data on concurrent dosing with ADT and docetaxel.